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Abstract
Background—Previous studies have provided substantial evidence on the association of 
Aggregatibacter actinomycetemcomitans (Aa), and its highly leukotoxic JP2 genotype, with 
localized aggressive periodontitis (LAP). The present study aims to evaluate the presence of JP2 in 
LAP individuals following periodontal treatment.
Methods—Sixty African American LAP patients between ages 5 and 25 years were examined. 
At baseline, pocket depth (PD), clinical attachment level (CAL), bleeding on probing (BoP) and 
plaque index were measured and subgingival plaque was collected from both LAP diseased sites 
and healthy sites for each participant. Patients received whole-mouth ultrasonic debridement, 
scaling and root planning and a 7-day prescription of amoxicillin and metronidazole. Participants 
were re-evaluated, re-sampled and received regular maintenance therapy at 3, 6 and 12-months 
post-treatment. PCR technique was used detect presence of the JP2 genotype before and after 
treatment.
Results—At baseline, the JP2 sequence was identified in 75% of LAP diseased sites and in 
56.67% of healthy sites. At 3, 6 and 12-months post-treatment, patient compliance was 40, 31 and 
31, respectively, and JP2 detection decreased to 17.5%, 6.45% and 3.23% respectively, in diseased 
sites (P<0.001) and to 2.5%, 3.23% and 0% respectively, in healthy sites (P<0.001). Clinical 
parameters of disease were also significantly reduced after therapy (p<0001). Additionally, 
significant correlations were observed between JP2 presence and mean PD (p < 0.002) and CAL 
(p < 0.001), post-therapy.
Conclusion—Periodontal therapy was successful in reducing clinical parameters of LAP and the 
subgingival presence of JP2 in diseased and healthy sites.
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Characterized by severe anatomical and physiological destruction of the periodontal 
structures supporting the first molars and/or incisors, localized aggressive periodontitis 
(LAP) is an inflammatory disease that typically presents in adolescent individuals that are 
otherwise systemically healthy. 1, 2 LAP prevalence varies substantially between age groups 
and ethnicities, however research evidence describes a more pronounced frequency of LAP 
occurrence within adolescent populations of African ancestry, significantly more so than 
Hispanic and Caucasian populations. 3–5 While the rationale behind this endemic remains to 
be elucidated, clinical investigations of Aggregatibacter actinomycetemcomitans (Aa), a 
resident bacterium of the oral microbiota may help provide possible explanations.6–8 One 
such explanation examines the concept of two separate etiologies for LAP; the first 
considers minimally leukotoxic genotypes of A. actinomycetemcomitans as opportunistic 
pathogens across several ethnic groups worldwide. The second, recognizes the highly 
leukotoxic JP2 genotype of A. actinomycetemcomitans as an exogenous pathogen that 
exhibits racial tropism towards persons of African descent and is presumed to employ 
interfamilial dissemination, 9 the latter also found for Aa. 10, 11 for Research has shown that 
individuals infected with this highly leukotoxic JP2 Aa have a higher risk of developing 
attachment loss than those infected with non-JP2 genotype. 8 A similar study reports 
statistical significance between the presence of the JP2 genotype and the conversion from a 
healthy periodontal state to a LAP diseased state with LAP susceptible African American 
families. 12 Furthermore, a number of studies have associated the JP2 clone with more 
severe forms of LAP. 13–15
The polymorphonuclear (PMN) and monocyte cell-specific leukotoxin assembled by all A. 
actinomycetemcomitans is produced in 10–20 times greater amounts in the JP2 genotypes 
than in the minimally pathogenic genotypes.16 Additionally, Brogan and coworkers 
describes this enhanced leukotoxicity as a consequence of a unique 530 base-pair deletion 
within the promoter region of the leukotoxin operon. This deletion subsequently allows the 
inclusion and participation of a second promoter in transcription of the leukotoxin gene 
thereby leading to greater production of the toxin. 16 Thus, this organism appears to be of 
great toxicity and strong association with this disease.
Although previous periodontitis treatment studies have shown significant correlations 
between the suppression of A. actinomycetemcomitans presence and reductions in the 
clinical parameters of aggressive periodontitis 17–20, the JP2 and non-JP2 genotype 
persistence after non-surgical treatment of LAP patients remains unclear. One study looked 
into JP2 genotype specifically after treatment of periodontitis patients. Cortelli et al.16 
conducted a study in which a group of Brazilian periodontitis participants harboring the JP2 
and the non-JP2 sequences were evaluated at baseline and re-evaluated at 12 months post 
scaling/root planning, systemic antibiotics and periodontal surgery. At 12 months, clinical 
measurements were significantly reduced in both groups, it was noted however, that the 
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presence of the JP2 genotype negatively affected the response to treatment. 21 Due to 
geographical changes on bacterial colonization of aggressive periodontitis, in specifically Aa 
JP2 genotype, it is important to evaluate the potential reduction of this virulent clone in 
different populations/continents after no-surgical therapy and the maintenance of such 
results long-term post-therapy.
We have recently reported our cross-sectional findings on the prevalence of the JP2 and non-
JP2 sequences of A. actinomycetemcomitans within a cohort of 60 African American 
children diagnosed with LAP, of whom (50) 83% carried the JP2 genotype and (17) 28.33% 
carried the non-JP2 genotype.22 Understanding host and bacterial response to periodontal 
treatment and disease progression/resolution during maintenance is crucial to the 
development of improved treatment protocols. Therefore, the objective of this longitudinal 
study is to investigate, within this population of LAP patients, the impact of mechanical and 
a single dose of systemic antibiotic therapy on the detection of JP2 and non-JP2 genotypes 
of A. actinomycetemcomitans, as well as possible concomitant impacts on the clinical 
manifestation of the disease over a 12-month period.
MATERIALS AND METHODS
Participant Population
The data reported herein was gathered from a subject group of 60 African American LAP 
patients with a baseline mean age of 13.25 ± 4.12 years; 42 with LAP affecting permanent 
dentition and 18 primary dentition (see Table 1 for demographic and clinical parameters). 
Participants were recruited from the Leon County Health Department (Tallahassee, FL) 
between April 2007 and November 2015, from the Dental Clinical Research Unit 
(Gainesville, FL) between February 2014 to March 2014, from the Duval County Health 
Department (Jacksonville, FL) between February 2014 and March 2016 and from Jackson 
County Health Department (Marianna, FL) between April 2015 and April 2016. All 
participants and legal guardians of participants under 18 received verbal briefing of the 
investigation, and written consent/assent was obtained before proceeding with the study. The 
study protocol was reviewed and approved by the Institutional Review Board at the 
University of Florida (IRB# 201400349) and is registered in Clinicaltrials.gov 
(#NCT01330719).
Study inclusion criteria were as follows: ages of 5 and 25 years old, systemically in good 
health as evidenced by medical history and a diagnosis of LAP according to criteria detailed 
in Armitage 1999 and Albandar 2014. 1,2 More specifically, patients should present at least 
two sites with pocket depths (PD) greater than or equal to 5mm, with bleeding on probing 
(BoP), clinical attachment levels (CAL) of 2mm or greater and bone loss detected by 
radiographs, on first molars and/or incisors, but in no more than two teeth other than first 
molars and incisors. Exclusion criteria: patient diagnosed with any systemic diseases or 
conditions that could influence the characteristics or clinical presentation of LAP (ex: 
diabetes, blood disorders etc.), patient who reported the use of antibiotics within 3 months 
prior to first visit, or use of any medications that could influence periodontal characteristics 
or interfere with response to periodontal treatment (ex: cyclosporine, phenytoin), pregnant 
and/or lactating women, and smokers.
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Clinical Examination & Sampling
At baseline, 3, 6 and 12 months the following clinical parameters were measure and six sites 
per tooth by previously calibrated examiners (LMS and PH): pocket depth (PD), clinical 
attachment level (CAL), bleeding on probing (BoP) and plaque index (PI) using a 
UNC-15mm§ probe and stored using a periodontal software**. Bitewing and periapical 
radiographs were taken to assess bone loss and further confirm diagnosis. Per patient, 
subgingival plaque was obtained from two LAP diseased sites (PD≥5mm, BoP, CAL≥2mm 
and radiographic bone loss) of which the deepest pockets were targeted and from two 
healthy similar sites (interproximal site, posterior or anterior, depending on diseased site 
sampled, PD≤3mm, no BoP, no CAL, no bone loss). Plaque samples were harvested using 
sterile absorbent endodontic paper points†† and stored at −80° C until processed.
Bacterial DNA extraction and JP2 sequence detection proceeded as previously described. 22 
Briefly, bacterial DNA was isolated from the subgingival plaque samples using the DNA 
Purification Kit, following the manufacturer instructions‡‡. Target sequences were amplified 
under standard polymerase chain reaction (PCR) conditions using a PCR Master Mix with 
HF buffer§§ and primers previously mentioned by Poulsen and coworkers: ltx3 (5′–
GCCGACACCAAAGACAAAGTCT-3′) and ltx4 (5′–
GCCCATAACCAAGCCACATAC-3′).23
Periodontal Treatment
The periodontal treatment methods employed within this study were performed by two 
calibrated examiners (LMS and PH) and are previously described in detail. 24 Treatment was 
administered subsequent to recording baseline periodontal parameters/sample collection and 
consisted of a full-mouth supra-subgingival debridement using an ultrasonic device***, 
scaling and root planning of diseased sites under local anesthesia, as needed. Additionally, 
patients were prescribed one single regimen of systemic antibiotics: a combination of 500mg 
amoxicillin and 250mg metronidazole25–27 (dosage adjusted for children <40 kg), t.i.d for 7 
days. Antibiotic compliance and side effects were verified at next visit with patient/parent, 
returned medication bottles and medication log. All patients received oral hygiene 
instructions and an accompanying oral care kit consisting of an electronic toothbrush†††, 
toothpaste, dental floss, and interproximal brushes as needed. Participants were requested to 
be present at 3, 6, and 12 month appointments after baseline for re-examination, at which 
they received additional full mouth supra-subgingival debridement with ultrasonic device, 
scaling and root planning of remaining diseased sites, as needed, and oral hygiene 
instructions. Patients did not receive additional antibiotics at follow up visits.
§Hu-Friedy, Chicago, IL
**Florida Probe Corporation Gainesville, FL††Paperpoints, medium size, Kerr Endodontics, Orange, CA‡‡MasterPure EPICENTRE Biotechnologies, Madison, WI, USA§§New England BioLabs Inc., Ipswich, MA, USA
***Cavitron Jet Plus, Dentsply, York PA†††Oral B Vitality TM Dual Clean, Proctor & Gamble, Cincinnati, OH, USA
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Statistical Analysis
Power analysis for this study was determined by baseline differences between LAP and 
controls as described previously.22 Post-Hoc power analysis run for the chi-square test for 
the main outcome variable (presence of JP2 post treatment in diseased sites) showed a power 
of 89.6% for the lowest N (31), at 12 months. Statistical analyses on the presence of JP2 and 
non-JP2 strains and correlations with clinical parameters were conducted using a statistical 
software‡‡‡. Chi-square and Fisher exact tests were used to compare the prevalence of 
positive strains (JP2 and non-JP2) at each timepoint, before and after treatment, out of a total 
of available sites (no data imputing performed). Pearson/Spearman correlations were used to 
correlate clinical parameters/reductions with the presence of JP2 strains and ANOVA/
Kruskal Wallis with Dunn’s multiple comparisons were used to compare clinical parameters 
before and after treatment among timepoints. Significance was determined at p value <0.05. 
All analysis were conducted using a statistical software§§§.
RESULTS
Sixty patients were included in this study. Our baseline analysis of JP2 genotype prevalence 
within this group has been recently published. 22 An impressive 83% of this study 
population carried the JP2 genotype in either a diseased site (75%) or in a healthy site 
(56.67%). The non-JP2 sequence proved to be significantly less pronounced within this 
group, presenting in only 18.33% of both diseased and heathy sites. Co-infection with both 
JP2 and non-JP2 sequences was observed in 15% of both diseased and healthy sites. 22 
Among the 60 participants enrolled at baseline, 40 (66.67%) returned at 3 months for post-
treatment evaluation and 31 (51.67%) returned at both 6 and 12 months (see supplementary 
Fig. 1 in online Journal of Periodontology).
A significant reduction in the prevalence of A. actinomycetemcomitans was observed 
following periodontal treatment. At 3, 6 and 12-months post-therapy, detection of the JP2 
genotype in LAP diseased sites had reduced to 17.5% (7/40), 6.45% (2/31) and 3.23% 
(1/31), respectively, compared to 75% at baseline (p < 0.0001, Fig. 1a). In LAP healthy sites, 
the post-treatment JP2 detection rate was 2.5%, 3.23% and 0% at 3, 6 and 12 months 
respectively, compared to 56.67% at baseline (P<0.001) (Fig 1b). In diseased sites, non-JP2 
sequence prevalence was also reduced from 18.33% at baseline to 0% at 3 months and to 
3.23% at both 6 and 12 months (p<0.01, Fig 2a), and in healthy sites from 18.33% at 
baseline to 2.5% at 3 months and 3.23% at 6 and 12 months respectively (p<0.01, Fig 2b). 
Interestingly, if we look at only those 31 patients that were evaluated at 12 months, their 
baseline proportion of diseased sites with JP2 clone is 68% (21 total) and only 1 patient of 
those 31 (3%) presented this species at 12 months post-therapy (P<0.001).
Similarly, significant improvements were also observed in PD and CAL post-treatment 
readings (Figure 3a). At baseline, PD and CAL means for LAP diseased sites measured 
6.55mm and 3.98mm respectively. Post-therapy evaluations at 3, 6 and 12 months reported 
reductions to the following mean PDs: 4.45mm, 4.32mm and 4.61mm and corresponding 
‡‡‡GraphPad Prism, version 5.00, San Diego California USA§§§GraphPad Prism, GraphPad Software, La Jolla, CA.
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CAL means: 1.75mm, 1.84mm and 1.84mm, respectively (p < 0.001, Fig 3a). Reductions in 
BoP were also noted across post-treatment time points, however they were non-significant 
(Table 1). The pre-therapy baseline data showed no significant difference between the mean 
PD and mean CAL of LAP diseased sites that were positive for the JP2 sequence and those 
that were negative for JP2 sequence. 22 However, after treatment, significant positive 
correlations were observed between JP2 presence and PD (p=0.002 and r2=0.2889) and 
between JP2 presence and CAL (p<0.001 and r2=0.3619). A significant difference was noted 
between the PD and CAL of sites with and without the JP2 sequence at baseline and the PD 
and CAL of the same sites at the subsequent visits (p < 0.001), markedly, as the number of 
JP2 positive sites decreased due to treatment, so did the PD and CAL readings (Fig. 3b). It is 
important to note that there were no reported side effects with the use of this regimen by any 
LAP participant.
DISCUSSION
Research describes the microbiological environments associated with periodontal health, as 
a homeostatic balance in which potentially pathogenic species are presumed to naturally 
exist within the indigenous microflora. Colonization by these pathogens is kept to a 
minimum due to competition from commensal species.28 However, slight disturbances in the 
subgingival environment may be disruptive to this homeostasis thereby enabling antagonistic 
species to thrive and outcompete commensal ones. Such shifts in the microbial ecosystems 
are believed to be the driving forces behind the development of inflammatory diseases of the 
periodontium. 28–30
Microbial analyses of the subgingival microflora of LAP subjects indicates that these 
individuals maintain a collection of organisms that is significantly different from that of 
heathy individuals. 31 Specifically, within African American adolescent populations, the 
presence of the highly virulent JP2 genotype of A. actinomycetemcomitans has garnered 
much attention; this species, as evidenced by a number of studies appears to be strongly 
implicated in etiology of localized aggressive periodontitis in this group. 9, 31–34 Findings 
from our preliminary investigation concerning the prevalence of the JP2 genotype within a 
group of 60 African American LAP patients further substantiates this claim, as 83% of this 
study population harbored the highly leukotoxic JP2 genotype. 22 The purpose of this study 
was to evaluate the impact of periodontal treatment on the stability of the JP2 genotype of 
Aa as it related to the effectiveness of treatment on the clinical presentation of LAP within 
this group.
The results of the present study are consistent with previous treatment studies that have 
reported a positive correlation between the reduction of A. actinomycetemcomitans and the 
resolution of LAP. 17, 35 Considering both LAP diseased and healthy sites within the present 
study, we observed significant reductions in the detectability of both the JP2 and non-JP2 
sequences following mechanical debridement and antibiotic therapy (Figs. 1 and 2). A 
correlation between diseased sites harboring or not harboring the JP2 sequence at baseline 
alone, was not significant with the mean PD and CAL in those sites; this could be due to too 
few LAP sites negative for JP2 (15) as compared to JP2 positive sites (45), and the disease 
being clinically very uniform among those sites (all sites deeper than 5mm). However, 
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following treatment, a correlation was found between the JP2 and both PD and CAL, i.e. the 
sites with persistent JP2 sequence after treatment presented significantly deeper PD and 
higher CAL levels that the JP2 negative sites (figure 3). Furthermore, we noted that the 
elimination of the JP2 genotype (the conversion of a site from JP2 positive to JP2 negative) 
in the long term after treatment corresponded to improvements and maintenance in the 
clinical presentation of LAP. Specifically, both PD and CAL measurements were noted to be 
significantly reduced after treatment, and remained reduced, for up to 12-months post-
therapy. These results corroborate with previous findings, where the elimination of JP2 was 
correlated with positive clinical presentation. 21 These correlations presented here provide 
further evidence for the implication of the JP2 genotype as an associated pathogen in LAP 
disease and attests for the first time the effectiveness of this non-surgical treatment protocol 
for this population in 12 months post-therapy. In fact, the long-term clinical benefits and 4-
year maintenance of this treatment protocol has been previously reported for all LAP 
patients in this trial. 36 Noteworthy, this is a one-time regimen of antibiotics for the 
treatment of this population at baseline and they are followed by regular maintenance 
following this treatment. Thus, the significant reduction of this pathogen long-term with one 
time antibiotic use is of extreme clinical benefit here for this disease.
The aforementioned treatment study by Cortelli et al. 2009 21 presents results comparable to 
the present study, furthermore the authors report that those patients infected with the non-
JP2 genotype appeared to respond more favorably to treatment than those infected with the 
JP2 genotype. Reductions in the detectability of non-JP2 clone of A.a were also observed in 
the present study 12-months post-treatment, however, the non-JP2 genotype was only 
present in 28.33% of sites in the present study, majority of which occur as a co-infection 
with the JP2 sequence. Thus, we were not able to statistically compare the effects of non-JP2 
alone in the response to treatment in the present investigation. However, our results 
regarding JP2 do corroborate with this previous investigation as previously mentioned.
The JP2 genotype was also detected in 56.67% of healthy sites examined at baseline, and 
after treatment, significant reduction in the presence of JP2 genotype was observed in these 
sites as well. The notable presence of this bacterium within healthy sites of LAP patients and 
within the heathy control group (40%) analyzed previously 22 indicates that simply detecting 
the JP2 sequence may not be sufficient to predict disease onset. Nonetheless, the presence of 
this bacterial genotype may increase host susceptibility for commensal-pathogen imbalance. 
This, along with genetic predisposition, and a heightened host responsiveness, 37 may lead 
to disease onset. Interesting to also note here that our previous study looking at a slightly 
smaller sample size of this cohort (51 LAP patients) and under a 16S-rRNA-microarray 
based assay (HOMIM) have shown >50% of diseased sites harboring Aa (OT531) in this 
population, 31 although the specific JP2 genotype evaluated here was more prevalent, as 
detected with regular PCR (75% of diseased sites). It is also important to note that the 
detection rate of this species after treatment could have been higher if more sites were 
collected at baseline and post-treatment. 38 However, given the localization of this specific 
disease (only a few sites in the mouth effected), the attrition data (missed appointments 
following treatment, which is a common occurrence for this population) and the very low 
prevalence of this disease, a higher number of post-treatment sample collection was not 
possible in the present investigation. Additionally, the fact that some patients missed 
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timepoints and therefore proper maintenance could lead to recurrence of the JP2 
colonization. However, despite these limitations, it is important to note that the present study 
still showed a high prevalence of JP2 at baseline, followed by a very low detection rate of 
this species post-treatment, with a power of >80%.
Another limitation in this study is the lack of quantification of the actual bacterial load 
within the sites analyzed. This study only evaluated the presence/absence of this species. 
The actual amount of this species load in the sites could potentially influence the onset and 
the severity of LAP manifestation and consequently strongly influence response to 
treatment. However, we were able to show that this treatment protocol was able to 
significantly reduce the detection of JP2 in LAP and maintain low detection rates, along 
with clinical stability, over 12 months post-therapy.
CONCLUSIONS
This study showed that mechanical periodontal therapy with a single regimen of amoxicillin 
and metronidazole was successful in reducing and maintaining a low rate of detection of JP2 
in diseased and healthy sites of African Americans diagnosed with LAP, along with a 
significant reduction and stability of clinical parameters of the disease, 12 months post-
therapy.
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Figure 1. 
Figure 1A. Chi-square and Fisher exact tests show difference between baseline (BL) and all 
timepoints after treatment on the frequencies of JP2 positive diseased sites in LAP patients 
(****P<0.0001).
Figure 1B. Chi-square and Fisher exact tests show difference between baseline (BL) and all 
timepoints after treatment on the frequencies of JP2 positive healthy sites in LAP patients 
(****P<0.0001).
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Figure 2. 
Figure 2A. Chi-square and Fisher exact tests show difference between baseline (BL) and all 
timepoints after treatment on the frequencies of non-JP2 positive diseased sites in LAP 
patients (**P<0.01).
Figure 2B. Chi-square and Fisher exact tests show difference between baseline (BL) and all 
timepoints after treatment on the frequencies of non-JP2 positive healthy sites in LAP 
patients (**P<0.01).
Burgess et al. Page 12
J Periodontol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
Figure 3A. Anova (Kruskal-wallis with Dunn’s multiple comparisons) show significant 
differences between baseline (BL) mean pocket depth (PD) and mean clinical attachment 
levels (CAL) of the sampled diseased site and all other timepoints, up to 12 months 
(****p<0.001).
Figure 3B. Spearman correlation show significant positive correlation between JP2 (JP2+) 
presence and PD (r=0.2889, p=0.002) and CAL (r=0.3619, p<0.0001) and Mann-Whitney 
tests also showed a significant difference between JP2+ and JP2 negative (JP2-) sites in 
terms of PD (***p=0.0002) and CAL (****p<0.001).
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Table 1
Demographics and Clinical Parameters before and after treatment.
Time point Baseline 3 months 6 months 12 months
Subjects, n 60 40 31 31
Age, years ± SD 13.25 ± 4.12 14.025 ± 3.83 13.48 ± 4.37 14.39 ± 4.04
Sex, female:male 29:31 22:18 15:16 15:16
Mean PD site, mm 6.55 ± 1.78*** 4.45 ± 1.69 4.32 ± 1.81 4.61 ± 1.94
Mean CAL site, mm 3.98 ± 1.85*** 1.75 ± 2.11 1.84 ± 2.16 1.84 ± 2.22
PD > 4mm, % 16.07 ± 10.74*** 8.35 ± 7.41 7.45 ± 5.49 7.71 ± 6.77
BoP, % 20.28 ± 23.87** 12.73 ± 8.00 12.39 ± 9.06 12.58 ± 9.28
Plaque index, % 36.57 ± 23.87 24.8 ± 14.56* 32.19 ± 25.32 28.06 ± 17.51
SD=standard deviation,
***p<0.0001,
**
P<0.01 all timepoints compared to baseline.
*
P<0.05 compared to baseline.
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